We are excited to announce that Lumito and Truly Labs are joining forces in a strategic partnership to develop innovative, value-driven solutions that provide both companies with a competitive edge in tissue analysis.
“We are truly happy about this partnership where we will work together to improve the quality and objectivity of tissue analysis. Combining our skills, experience and company profiles in a partnership has big potential to fill the unmet needs in, for example, pharma development”, says Sanna Wallenborg, CEO, and Anders Wallseth, Commercialisation Sr Advisor & Project Lead, at Lumito.
“We are really looking forward to work together with Lumito to explore how their unique tissue analysis platform can add value to our services in drug development. Specifically, we are looking forward to adding higher selectivity and sensitivity in combination with possibility to better quantify protein expression levels”, says Karin von Wachenfeldt, CEO, and Charlott Brunmark, CSO, at Truly Labs.
Lumito will participate in the 10-year celebration at Truly Labs’ new facilities at Medicon Village on January 15th, where the Lumito offering and SCIZYS scanner will be showcased.
For further information, please contact:
Sanna Wallenborg, CEO Lumito
E-mail: sw@lumito.se
Ph: +4670-870 01 68
About Truly Labs
Truly Labs AB is a Contract Research Organization (CRO) providing customized in vitro and in vivo services to its customers. Truly Labs was founded in January 2015 as a subsidiary of Truly Translational AB. The Truly Labs’ team has a solid track record with scientific and experimental expertise and experience from drug research & development in both large pharma and biotech, and extensive experience of working with both small molecules and biologics. Truly Labs’ key therapeutic areas are inflammation, respiratory diseases, oncology and autoimmune diseases where we offer state of the art in vitro and in vivo technologies.
About Lumito
Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/